Lowest-Rated StocksLowest-RatedNASDAQ:FUSN Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis → The Petrodollar Scheme Comes to an End (From Colonial Metals) (Ad) Free FUSN Stock Alerts $21.55 0.00 (0.00%) (As of 06/4/2024 ET) Add Compare Share Share Today's Range$21.55▼$21.5550-Day Range$21.24▼$21.5552-Week Range$2.31▼$21.60VolumeN/AAverage Volume1.69 million shsMarket Capitalization$1.83 billionP/E RatioN/ADividend YieldN/APrice Target$20.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Fusion Pharmaceuticals alerts: Email Address Fusion Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.07 Rating ScoreUpside/Downside6.0% Downside$20.25 Price TargetShort InterestHealthy3.60% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.44) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.98 out of 5 starsMedical Sector777th out of 905 stocksBiological Products, Except Diagnostic Industry135th out of 150 stocks 2.0 Analyst's Opinion Consensus RatingFusion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on 1 buy rating, 13 hold ratings, and no sell ratings.Amount of Analyst CoverageFusion Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Fusion Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.60% of the outstanding shares of Fusion Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverFusion Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fusion Pharmaceuticals has recently decreased by 22.53%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFusion Pharmaceuticals does not currently pay a dividend.Dividend GrowthFusion Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FUSN. Previous Next 2.4 News and Social Media Coverage News SentimentFusion Pharmaceuticals has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Fusion Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for FUSN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows4 people have added Fusion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fusion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.75% of the stock of Fusion Pharmaceuticals is held by insiders.Percentage Held by Institutions72.85% of the stock of Fusion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fusion Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fusion Pharmaceuticals are expected to decrease in the coming year, from ($1.44) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fusion Pharmaceuticals is -15.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fusion Pharmaceuticals is -15.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFusion Pharmaceuticals has a P/B Ratio of 7.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Fusion Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.Read More FUSN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FUSN Stock News HeadlinesJune 4 at 4:05 PM | prnewswire.comAcquisition of Fusion Pharmaceuticals CompletedMay 31, 2024 | prnewswire.comFusion Pharmaceuticals Receives Final Court Order Approving ArrangementMay 30, 2024 | americanbankingnews.comFinancial Contrast: Fusion Pharmaceuticals (NASDAQ:FUSN) versus Aura Biosciences (NASDAQ:AURA)May 29, 2024 | prnewswire.comFusion Pharmaceuticals Shareholders Approve Acquisition by AstraZenecaMay 9, 2024 | prnewswire.comFusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate CancerMay 9, 2024 | businesswire.comFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNMay 7, 2024 | investorplace.comFUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024May 7, 2024 | prnewswire.comFusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program UpdatesApril 26, 2024 | msn.comTop 4 Health Care Stocks That May Plunge This MonthApril 26, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Laboratory (LH), Fusion Pharmaceuticals (FUSN) and Integer Holdings (ITGR)April 25, 2024 | prnewswire.comFusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim OrderApril 19, 2024 | morningstar.comFusion Pharmaceuticals Inc Ordinary SharesApril 17, 2024 | finance.yahoo.comFusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should KnowApril 17, 2024 | msn.comTD Cowen Downgrades Fusion Pharmaceuticals (FUSN)April 11, 2024 | finance.yahoo.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) is definitely on the radar of institutional investors who own 46% of the companyApril 9, 2024 | finance.yahoo.comFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024April 9, 2024 | prnewswire.comFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024April 3, 2024 | msn.comGenmab Buys ProfoundBio for $1.8B to Boost Oncology PortfolioMarch 28, 2024 | msn.comWhat Fusion Pharmaceuticals (NASDAQ:FUSN) Acquisition Means for InvestorsMarch 26, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSNMarch 20, 2024 | msn.comFUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023March 20, 2024 | stockhouse.comKuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law FirmMarch 20, 2024 | markets.businessinsider.comFusion Pharmaceuticals: Hold Rating Justified Amid Acquisition and Radiopharmaceutical Market DynamicsMarch 20, 2024 | finance.yahoo.comFusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program UpdatesMarch 20, 2024 | markets.businessinsider.comUnveiling 11 Analyst Insights On Fusion PharmaceuticalsSee More Headlines Receive FUSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/04/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FUSN CUSIPN/A CIK1805890 Webfusionpharma.com Phone289-799-0891FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$20.25 High Stock Price Target$24.00 Low Stock Price Target$15.00 Potential Upside/Downside-6.0%Consensus RatingHold Rating Score (0-4)2.07 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,900,000.00 Net Margins-4,136.55% Pretax Margin-5,084.07% Return on Equity-48.74% Return on Assets-36.87% Debt Debt-to-Equity Ratio0.21 Current Ratio10.64 Quick Ratio10.64 Sales & Book Value Annual Sales$2.04 million Price / Sales898.55 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book7.02Miscellaneous Outstanding Shares85,060,000Free Float78,468,000Market Cap$1.83 billion OptionableOptionable Beta-0.69 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. John F. Valliant Ph.D. (Age 53)Founder, CEO & Director Comp: $911.34kMr. Mohit Rawat (Age 44)President & Chief Business Officer Comp: $706.08kMr. John J. Crowley CPA (Age 50)CFO & Compliance Officer Comp: $719.82kDr. Eric Burak Ph.D. (Age 59)Chief Technology Officer Comp: $638.04kDr. Christopher Paul Leamon Ph.D. (Age 58)Chief Scientific Officer Ms. Amanda CraySenior Director of Investor Relations & Corporate CommunicationsMs. Maria D. Stahl (Age 53)Chief Legal Officer Mr. Eric S. Hoffman Ph.D. (Age 54)Senior Vice President of Business Development Dr. Cara Ferreira Ph.D.Chief of StaffDr. Joanne SchindlerExecutive Vice President of Medical Director & Clinical DevelopmentMore ExecutivesKey CompetitorsY-mAbs TherapeuticsNASDAQ:YMABProgenics PharmaceuticalsNASDAQ:PGNXMeiraGTxNASDAQ:MGTXExelixisNASDAQ:EXELRevolution MedicinesNASDAQ:RVMDView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 28,917 shares on 5/20/2024Ownership: 0.034%Bluefin Capital Management LLCBought 10,000 shares on 5/20/2024Ownership: 0.012%KRYGER CAPITAL LtdBought 100,284 shares on 5/16/2024Ownership: 0.118%California State Teachers Retirement SystemBought 39,041 shares on 5/16/2024Ownership: 0.046%Beryl Capital Management LLCBought 16,191 shares on 5/16/2024Ownership: 0.019%View All Institutional Transactions FUSN Stock Analysis - Frequently Asked Questions Should I buy or sell Fusion Pharmaceuticals stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last year. There are currently 13 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" FUSN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FUSN, but not buy additional shares or sell existing shares. View FUSN analyst ratings or view top-rated stocks. What is Fusion Pharmaceuticals' stock price target for 2024? 14 analysts have issued 1 year price objectives for Fusion Pharmaceuticals' shares. Their FUSN share price targets range from $15.00 to $24.00. On average, they predict the company's stock price to reach $20.25 in the next year. This suggests that the stock has a possible downside of 6.0%. View analysts price targets for FUSN or view top-rated stocks among Wall Street analysts. How have FUSN shares performed in 2024? Fusion Pharmaceuticals' stock was trading at $9.61 at the start of the year. Since then, FUSN stock has increased by 124.2% and is now trading at $21.55. View the best growth stocks for 2024 here. Are investors shorting Fusion Pharmaceuticals? Fusion Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 3,060,000 shares, a decrease of 22.5% from the April 30th total of 3,950,000 shares. Based on an average trading volume of 1,820,000 shares, the short-interest ratio is currently 1.7 days. View Fusion Pharmaceuticals' Short Interest. When is Fusion Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our FUSN earnings forecast. How were Fusion Pharmaceuticals' earnings last quarter? Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.74% and a negative net margin of 4,136.55%. What ETFs hold Fusion Pharmaceuticals' stock? ETFs with the largest weight of Fusion Pharmaceuticals (NASDAQ:FUSN) stock in their portfolio include ProShares Merger ETF (MRGR).IQ Merger Arbitrage ETF (MNA). What other stocks do shareholders of Fusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK). When did Fusion Pharmaceuticals IPO? Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Fusion Pharmaceuticals' major shareholders? Fusion Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Blair William & Co. IL (0.92%), Jane Street Group LLC (0.75%), Privium Fund Management B.V. (0.30%), Chicago Capital Management LLC (0.20%), Equitec Proprietary Markets LLC (0.00%) and Maso Capital Partners Ltd (0.18%). Insiders that own company stock include John Valliant and Steven Gannon. View institutional ownership trends. How do I buy shares of Fusion Pharmaceuticals? Shares of FUSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FUSN) was last updated on 6/5/2024 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club| SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals| Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media| SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press| SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.